Dopamine-Related Genotypes and Physical Activity Change During an Intervention: The Lifestyle Interventions and Independence for Elders Study
Overview
Authors
Affiliations
Objectives: To determine whether intervention-induced physical activity (PA) changes in sedentary older adults differed according to dopamine-related genotype.
Design: Randomized clinical trial (Lifestyle Interventions and Independence for Elders Trial (2010-13)).
Setting: Multicenter study, 8 U.S.
Locations:
Participants: Volunteer sample of sedentary adults aged 70 to 89 at risk of disability (N=1635).
Interventions: Structured PA versus health education (HE) for an average of 2.6 years.
Measurements: Single-nucleotide polymorphisms of dopamine-related genes (dopamine receptor (DR) D1, DRD2, DRD3, and catechol-O-methyltransferase (COMT)) were assessed. Average moderate to vigorous PA (MVPA) was calculated using accelerometry (min/d) at baseline and 6, 12, and 24 months. Between-arm MVPA differences according to genotype and genotype with square root-transformed MVPA separately according to arm were tested, stratified according to race, and adjusted for multiple comparisons.
Results: White participants in the PA arm (n=513) had higher average square root transformed MVPA (4.91±1.91)than those in the HE arm (n=538) (4.51±1.82) (p=.001). Between-arm differences were greater for DRD2 Met/Met (high dopamine; HE: 4.76±1.80, PA: 5.53±1.60, p=.03) than Val/Val (low dopamine; HE: 4.58±1.92, PA: 4.81±1.83, p=.16); results were similar for COMT. In the PA arm, DRD2 Met/Met was associated with higher average MVPA (5.39±2.00) than Met/Val (4.46±2.51) (p=.01) and Val/Val (4.65±2.71) (p=.01). There were no associations for other genes. Associations were not significant in blacks but followed similar trends.
Conclusion: Higher dopamine signaling may support changes in PA during an intervention. The role of dopamine-related pathways in promoting PA participation and enhancing response to interventions in sedentary older adults should be studied.
Trial Registration: clinicaltrials.gov Identifier: NCT01072500.
Huminska-Lisowska K Int J Mol Sci. 2024; 25(21).
PMID: 39519153 PMC: 11546834. DOI: 10.3390/ijms252111602.
Zhang L, Chen Y, Fan Y, Shi L Sci Rep. 2024; 14(1):7116.
PMID: 38531892 PMC: 10965903. DOI: 10.1038/s41598-024-57080-4.
Simonsson E, Stiernman L, Lundquist A, Rosendahl E, Hedlund M, Lindelof N Front Hum Neurosci. 2022; 16:997131.
PMID: 36438629 PMC: 9691986. DOI: 10.3389/fnhum.2022.997131.
Ruiz-Tejada A, Neisewander J, Katsanos C Brain Sci. 2022; 12(3).
PMID: 35326289 PMC: 8946175. DOI: 10.3390/brainsci12030333.
Lee C, Moon H, Kang J, Choi J, Kwon J Brain Behav. 2021; 12(1):e2459.
PMID: 34904796 PMC: 8785622. DOI: 10.1002/brb3.2459.